

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Vatera Healthcare Partners LLC</u>  (Last) (First) (Middle) <u>C/O VATERA HOLDINGS LLC</u> <u>499 PARK AVENUE, 23RD FLOOR</u>  (Street) <u>NEW YORK NY 10022</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>MELINTA THERAPEUTICS, INC.</u> <u>/NEW/ [ MLNT ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/05/2018</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/05/2018		P <sup>(1)</sup>		1,777,778	A	\$13.5	8,507,237	D <sup>(3)(5)</sup>	
Common Stock	01/05/2018		P <sup>(1)</sup>		2,000,000 <sup>(2)</sup>	A	\$13.5	8,729,459	I <sup>(4)(5)</sup>	See Footnotes <sup>(4)(5)</sup>
Common Stock	01/05/2018		P <sup>(1)</sup>		2,000,000 <sup>(2)</sup>	A	\$13.5	8,729,459	I <sup>(4)(5)</sup>	See Footnotes <sup>(4)(5)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>Vatera Healthcare Partners LLC</u>  (Last) (First) (Middle) <u>C/O VATERA HOLDINGS LLC</u> <u>499 PARK AVENUE, 23RD FLOOR</u>  (Street) <u>NEW YORK NY 10022</u>  (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person*		
<a href="#">VATERA HOLDINGS LLC</a>		
(Last)	(First)	(Middle)
C/O VATERA HOLDINGS LLC		
499 PARK AVENUE, 23RD FLOOR		
(Street)		
NEW YORK	NY	10022
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
<a href="#">Ferro Kevin</a>		
(Last)	(First)	(Middle)
C/O VATERA HOLDINGS LLC		
499 PARK AVENUE, 23RD FLOOR		
(Street)		
NEW YORK	NY	10022
(City) (State) (Zip)		

**Explanation of Responses:**

1. See Exhibit 99.1.
2. See Exhibit 99.1.
3. See Exhibit 99.1.
4. See Exhibit 99.1.
5. See Exhibit 99.1.

**Remarks:**

Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filers' Signatures

[VATERA HEALTHCARE PARTNERS LLC, By: Vatera Holdings LLC, its Manager, By: /s/ Kevin Ferro, Title: Chief Executive Officer, Chief Investment Officer and Managing Member](#) 01/09/2018

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

## Explanation of Responses

- (1) On January 5, 2018, the Issuer consummated the transactions contemplated by the Purchase and Sale Agreement, dated November 28, 2017 (the "Purchase Agreement"), with The Medicines Company ("Medco"), pursuant to which the Issuer acquired the capital stock of certain subsidiaries of MedCo and certain other assets related to MedCo's infectious disease business unit. Pursuant to and in accordance with the terms of the letter, dated November 28, 2017 (the "Equity Commitment Letter"), between Vatera Healthcare Partners LLC and the Issuer, on January 5, 2018, concurrent with the closing of the transactions contemplated by the Purchase Agreement, Vatera Healthcare Partners LLC purchased 1,777,778 shares of Common Stock for an aggregate purchase price of \$24,000,000, or \$13.50 per share, and VHPM Holdings LLC, as an assignee of Vatera Healthcare Partners LLC under the Equity Commitment Letter, purchased 222,222 shares of Common Stock for an aggregate purchase price of \$3,000,000, or \$13.50 per share.
- (2) Includes 1,777,778 shares of Common Stock purchased directly by Vatera Healthcare Partners LLC and 222,222 shares of Common Stock purchased directly by VHPM Holdings LLC.
- (3) Represents shares of Common Stock held directly by Vatera Healthcare Partners LLC, a Reporting Person on this Form 4.
- (4) Vatera Holdings LLC is the manager of Vatera Healthcare Partners LLC and VHPM Holdings LLC and Kevin Ferro serves as the Chief Executive Officer, Chief Investment Officer and Managing Member of Vatera Holdings LLC. Vatera Holdings LLC and Mr. Ferro are Reporting Persons on this Form 4. Pursuant to Rule 13d-3 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"), Vatera Holdings LLC and Mr. Ferro may be deemed to beneficially own the shares owned directly by Vatera Healthcare Partners LLC and VHPM Holdings LLC. Each of Vatera Holdings LLC and Mr. Ferro disclaims beneficial ownership of any shares owned by Vatera Healthcare Partners LLC or VHPM Holdings, except to the extent of its or his pecuniary interest therein.
- (5) Mr. Ferro serves on the Board of Directors of the Issuer (the "Board"), together with Cecilia Gonzalo, a managing director of Vatera Holdings LLC, and Thomas P. Koestler, Ph.D., an executive director of Vatera Holdings LLC. Solely for purposes of Section 16 of the Exchange Act, Vatera Healthcare Partners LLC, VHPM Holdings LLC and Vatera Holdings LLC may be deemed to be directors-by-deputization as a result of the service of such persons on the Board. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the Board approved the acquisition of any direct or indirect pecuniary interest in any and all shares by the Reporting Persons as a result of or in connection with the transactions reported in this Form 4.

JOINT FILERS' SIGNATURES

VATERA HOLDINGS LLC

By: /s/ Kevin Ferro

-----

Name: Kevin Ferro

Title: Chief Executive Officer, Chief Investment  
Officer and Managing Member

By: /s/ Kevin Ferro

-----

Kevin Ferro